Cellular engineering, precision medicine, and using G protein-coupled receptors to treat heart failure and other conditions. That’s the focus of the three biotechnology companies that made the top 10 for venture investment deals last quarter. Biotechnology was the second largest sector for investment with $1.3 billion going into 103 deals, a 41 percent increase, according to a quarterly report by PwC and the National Venture Capital Association.
To read the original article: What’s special about the 3 biotechs in the top 10 for Q2 venture investments? | MedCity News
